Cargando…
PCSK9 as a Target for Development of a New Generation of Hypolipidemic Drugs
PCSK9 has now become an important target to create new classes of lipid-lowering drugs. The prevention of its interaction with LDL receptors allows an increase in the number of these receptors on the surface of the cell membrane of hepatocytes, which leads to an increase in the uptake of cholesterol...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778893/ https://www.ncbi.nlm.nih.gov/pubmed/35056760 http://dx.doi.org/10.3390/molecules27020434 |